Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

US Market Report for Ulcerative Colitis Immunology Drugs 2018 - MedCore

Reportlinker
Posted on: 07 Nov 17
US Market Report for Ulcerative Colitis Immunology Drugs 2018 - MedCore

PR Newswire

NEW YORK, Nov. 6, 2017

NEW YORK, Nov. 6, 2017 /PRNewswire/ --


General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends



Read the full report: https://www.reportlinker.com/p05175236


- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions

Colonoscopy procedures, blood tests and stool samples are commonly used in diagnosis of ulcerative colitis as well as medical imaging and description of the disease and symptoms. These tests can also help to rule out other disease that may occur with similar symptoms (Crohn's disease, diverticulitis).

Treatment options include medication to control the symptoms, lifestyle and dietary changes, reduction of stress, moderate activity and exercise. A mild form of UC requires over-the-counter medicines for diarrhea (such as Imodium). More severe form of the disease requires prescription medicines, such as aminosalicylates, steroid medicines or other medicines that reduce the body's immune response.
Acute treatment involves antibiotics, anti-inflammatory drugs and corticosteroids. Prolonged use of corticosteroids has significant side-effects; as a result, they are, in general, not used for long-term treatment. Aminosalicylates are often more effective in ulcerative colitis than in Crohn's disease. This treatment showed positive results in mild to moderate UC.

Another treatment option includes biologic agents, including an anti-tumor necrotizing factor-? (anti-TNF-?) agent. Currently available biologic agents include HUMIRA® (adalimumab) and its biosimilars Amjevita™ and Imraldi®, REMICADE® (infliximab) and its biosimilar Flixabi®, SIMPONI® (golimumab), Renflexis™ (Infliximab-abda) and ENTYVIO® (vedolizumab).

Abstract
Ulcerative colitis (UC) is a type of an inflammatory bowel disease (IBD). Ulcerative colitis and Crohn's disease are the most common type of the IBD. Both diseases affect the GI system with similar symptoms while the course of the diseases and treatments may be different. UC usually affects large intestine (rectum and colon), while CD can affect any part of the GI tract.

UC causes an inflammation and cores (ulcers) in the colon and usually affects the sigmoid colon (lower section of a large intestine) and rectum. The disease may affect people at any age, but usually it is diagnosed in people before the age of 30. UC can be controlled with medication and in severe cases can even be treated by a surgical removal of the entire large intestine.

Scope
2014-2024

Read the full report: https://www.reportlinker.com/p05175236

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

https://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/us-market-report-for-ulcerative-colitis-immunology-drugs-2018---medcore-300550606.html

SOURCE Reportlinker

PR Newswire
www.prnewswire.com

Last updated on: 07/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.